Pilot-scale comparison of microfiltration/reverse osmosis and ozone/ biological activated carbon with UV/hydrogen peroxide or UV/free chlorine AOP treatment for controlling disinfection byproducts during wastewater reuse

摘要

Ozone and biological activated carbon (O-3/BAC) is being considered as an alternative advanced treatment process to microfiltration and reverse osmosis (MF/RO) for the potable reuse of municipal wastewater. Similarly, the UV/free chlorine (UV/HOCl) advanced oxidation process (AOP) is being considered as an alternative to the UV/hydrogen peroxide (UV/H2O2) AOP. This study compared the performance of these alternative treatment processes for controlling N-nitrosamines and chloramine-reactive N-nitrosamine and halogenated disinfection byproduct (DBP) precursors during parallel, pilot-scale treatment of tertiary municipal wastewater effluent. O-3/BAC outperformed MF/RO for controlling N-nitrosodimethylamine (NDMA), while MF/RO was more effective for controlling N-nitrosomorpholine (NMOR) and chloramine-reactive NDMA precursors. The UV/H2O2 and UV/HOCI AOPs were equally effective for controlling N-nitrosamines in O-3/BAC effluent, but UV/HOCI was less effective for controlling NDMA in MF/RO effluent, likely due to the promotion of dichloramine under these conditions. MF/RO was more effective than O-3/BAC for controlling chloramine-reactive halogenated DBP precursors on both a mass and toxicity-weighted basis. UV/H2O2 AOP treatment was more effective at controlling the toxicity-weighted chloramine-reactive DBP precursors for most halogenated DBP classes by preferentially degrading the more toxic brominated species. However, the total toxicity-weighted DBP precursor concentrations were similar for treatment by either AOP because UV/H2O2 AOP treatment promoted the formation of iodoacetic acid, which exhibits a very high toxic potency. The combined O-3/BAC/MF/RO train was the most effective for controlling N-nitrosamines and the total toxicity-weighted DBP precursor concentrations with or without treatment by either AOP. (C) 2019 Elsevier Ltd. All rights reserved.